Vonoprazan

Introduction Overview

Generic Name

vonoprazan

Brand Name

Voquezna

Dosage Form

oral tablet

Drug Class

Proton pump inhibitors (Potassium-competitive acid blocker)

Pharmacokinetics

Absorption:
Vonoprazan is efficiently absorbed via the gastrointestinal tract after oral administration. Its bioavailability allows for rapid onset of acid suppression effects. Unlike traditional proton pump inhibitors (PPIs), vonoprazan does not require acid activation, allowing a more consistent and faster inhibition of gastric acid secretion. Peak plasma concentrations are typically achieved within 1 to 2 hours post-dose. Food intake does not significantly affect the absorption of vonoprazan, permitting dosing with or without meals, a clinical advantage enhancing patient compliance.

Distribution:
Vonoprazan exhibits a moderate volume of distribution, reflective of its ability to distribute into gastric parietal cells, the primary site of action. Plasma protein binding is moderate to high, which stabilizes systemic circulation levels. Animal studies and human pharmacokinetic data indicate good penetration to gastric mucosal tissue, ensuring effective local acid suppression. The drug's distribution patterns also include tissues involved in metabolism and elimination.

Metabolism:
Vonoprazan undergoes hepatic metabolism primarily through the cytochrome P450 enzyme system, involving CYP3A4 as the major isoenzyme, with additional minor contributions from CYP2B6, CYP2C19, CYP2D6, and CYP2C9. This metabolic profile influences potential drug interactions, especially with medications metabolized by CYP3A4. Unlike conventional PPIs which are acid-activated prodrugs, vonoprazan's stability allows it to act directly without prior activation, contributing to a more predictable pharmacodynamic response. Metabolites formed are generally inactive.

Elimination:
The elimination of vonoprazan occurs predominantly via hepatic metabolism, with subsequent excretion of metabolites primarily through feces and to a lesser extent in urine. The terminal half-life allows once-daily dosing in most indications; however, dosing adjustments may be warranted in patients with significant hepatic or renal impairment. Renal clearance is minor due to the predominant hepatic route. Drug accumulation in chronic therapy appears minimal based on available pharmacokinetic studies. Clinical monitoring is recommended for long-term use due to potential mineral imbalances caused by hypochlorhydria.

Dosage Forms

Available Dosage Forms:
Voquezna is available as oral tablets in two strengths: 10 mg and 20 mg. These immediate-release tablets are formulated to be swallowed whole without crushing or chewing. The tablets contain inactive ingredients including ascorbic acid, croscarmellose sodium, ferric oxide red (20 mg tablet), ferric oxide yellow (10 mg tablet), fumaric acid, hydroxypropyl cellulose, hypromellose, magnesium stearate, mannitol, microcrystalline cellulose, polyethylene glycol 8000, and titanium dioxide.

Dosages for Adults and Adolescents:
- Erosive Esophagitis Healing: 20 mg once daily for 8 weeks.
- Maintenance of Erosive Esophagitis Healing: 10 mg once daily for up to 6 months.
- Relief of Heartburn Associated with Non-Erosive Gastroesophageal Reflux Disease (GERD): 10 mg once daily for 4 weeks.
- Helicobacter pylori Eradication (Combination Therapy):
* Triple Therapy: Voquezna 20 mg twice daily plus amoxicillin 1000 mg twice daily and clarithromycin 500 mg twice daily for 14 days.
* Dual Therapy: Voquezna 20 mg twice daily plus amoxicillin 1000 mg three times daily for 14 days.

Specific Patient Populations:
- Patients with hepatic impairment may require dose adjustment given hepatic metabolism.
- Patients with renal impairment should be monitored carefully although no explicit dose adjustment is currently established.
- Voquezna may be used with caution during pregnancy and breastfeeding as safety data are limited.
- Pediatric dosing has not been established; hence use is restricted to adults.

Clinical guidelines emphasize adherence to specified treatment durations and close monitoring for adverse effects during long-term therapy, especially beyond one year, due to increased risk of gastric mucosal changes.

Mechanism Of Action

Vonoprazan, the active molecule in Voquezna, is a potassium-competitive acid blocker (PCAB) that exerts potent suppression of gastric acid secretion by selectively inhibiting the potassium-binding site of the H+/K+-ATPase enzyme located in the parietal cells of the gastric mucosa. This differs mechanistically from conventional proton pump inhibitors (PPIs), which irreversibly inhibit the proton pump only after requiring acid activation within acidic canaliculi. Vonoprazan's reversible and direct inhibition does not require acid activation, allowing immediate and sustained acid suppression.

At the cellular level, vonoprazan binds competitively to the potassium-binding site on the gastric H+/K+-ATPase enzyme, blocking the exchange of potassium ions necessary for the proton pump to function. This impedes the final critical step of acid secretion into the gastric lumen, thereby decreasing both stimulated and basal gastric acid output. The blockade results in elevated gastric pH levels rapidly, typically maintaining intragastric pH above 4 for extended periods longer than traditional PPIs.

Biochemically, the reversible inhibition leads to a faster onset of action and more consistent acid suppression throughout the dosing interval compared to PPIs, which often exhibit delayed onset due to need for acid activation and irreversible binding requiring new enzyme synthesis for effect loss. Additionally, vonoprazan’s distinct mechanism minimizes the variability seen with CYP2C19 metabolism due to less reliance on this pathway, allowing more uniform plasma concentrations and therapeutic effects across diverse genetic populations.

Clinically, this potent acid suppression facilitates the healing of erosive esophagitis, relief of gastroesophageal reflux disease (GERD) symptoms, and enhances the efficacy of antibiotic regimens for Helicobacter pylori eradication by improving gastric environment conditions. Research and clinical trials consistently demonstrate that vonoprazan provides superior or non-inferior acid control relative to PPIs such as esomeprazole or lansoprazole, with faster symptom relief and healing rates, marking it as a significant advancement in acid-related disorder management.

Pharmacological Actions

Potassium-competitive reversible inhibition of gastric H+/K+-ATPase proton pump.
Rapid, potent, and sustained suppression of gastric acid secretion.
Reduction of both basal and stimulated gastric acid output.
Improvement of intragastric pH maintaining >4 for prolonged periods.
Enhancement of antibiotic efficacy in Helicobacter pylori eradication through optimized gastric acidity.
More consistent plasma levels due to reduced dependence on CYP2C19 metabolism.
Faster onset of action compared to traditional proton pump inhibitors.
Promotion of mucosal healing in erosive esophagitis.
Alleviation of heartburn and acid reflux symptoms.
Potential reduction in variability of response among diverse CYP2C19 genotypes.
Protective effect against acid-related gastric mucosal injury.
Minimal food effect allowing dosing without meal consideration.
Enables maintenance therapy of acid-related disorders with lower dosage.
May reduce risk of nocturnal acid breakthrough compared to PPIs.
Can be combined effectively with antibiotics in triple or dual therapy for H. pylori.

Therapeutic Or Clinical Uses

Healing of erosive esophagitis in adults over an 8-week treatment course.
Maintenance therapy to prevent recurrence of erosive esophagitis for up to 6 months.
Relief of heartburn symptoms associated with non-erosive gastroesophageal reflux disease (GERD).
Eradication of Helicobacter pylori infection in combination with antibiotics (amoxicillin and clarithromycin or amoxicillin alone).
Reduction of gastric acid secretion in acid-related gastrointestinal disorders.
Treatment of acid reflux symptoms refractory to conventional proton pump inhibitors in some cases.
Potential off-label use in conditions where potent acid suppression is required, such as Zollinger-Ellison syndrome, pending clinical discretion.
Use as part of triple or dual therapy regimens for H. pylori to improve eradication rates due to potent acid suppression.
May be considered for patients with CYP2C19 polymorphisms who respond inadequately to traditional PPIs.
Management of symptomatic relief in patients with GERD-associated dyspepsia.
Prevention of acid-related mucosal injury during prolonged NSAID therapy (clinical discretion required).
Use in patients with acid-related disorders requiring medication compatible with once-daily dosing.
Alternative to PPIs for patients experiencing suboptimal response or intolerance to standard treatments.
Improvement in gastric mucosal healing in erosive diseases of the esophagus and stomach.
Adjunct therapy in gastrointestinal diagnostic procedures where acid suppression is necessary.

Side Or Adverse Effects

Diarrhea is among the most frequent gastrointestinal side effects.
Elevated blood pressure observed in some patients during therapy.
Indigestion symptoms, including dyspepsia and bloating.
Nausea and vomiting occurring sporadically.
Stomach inflammation and abdominal pain reported, including gastritis.
Urinary tract infections as noted during treatment courses.
Headache, particularly when vonoprazan is given with antibiotics for H. pylori.
Temporary alterations in taste (dysgeusia) reported especially with combination therapy.
Vaginal yeast infections associated with antibiotic co-administration.
Risk of acute tubulointerstitial nephritis, a serious kidney inflammation.
Potential development of Clostridioides difficile-associated diarrhea leading to severe colitis.
Increased susceptibility to bone fractures of hip, wrist, or spine with long-term or high-dose therapy.
Rare severe skin reactions including blistering, peeling, or severe dermatologic manifestations.
Vitamin B12 deficiency secondary to decreased gastric acid necessary for absorption.
Hypomagnesemia potentially causing seizures, muscle spasms, and arrhythmias.
Possible fundic gland polyps with prolonged use beyond one year.
Potential masking of gastric cancer symptoms necessitating monitoring.
Mild to moderate adverse events generally manageable with monitoring and supportive care.
Allergic reactions including rash and urticaria noted infrequently.

Precautions

Use cautiously in patients with known low magnesium, calcium, or potassium levels.
Monitor electrolytes regularly during prolonged therapy, especially magnesium and calcium.
Assess renal and hepatic function prior to and during treatment; dose adjustments may be needed.
Be vigilant for symptoms of acute kidney injury or tubulointerstitial nephritis.
Avoid abrupt discontinuation without medical advice to prevent rebound acid hypersecretion.
Patients should report any unusual skin reactions or severe dermatologic symptoms immediately.
Vitamin B12 levels should be monitored during long-term treatment for potential deficiencies.
Consider risk-benefit in patients with a history of osteoporosis or bone fractures before prolonged use.
Inform healthcare provider of all concurrent medications to avoid interactions.
Use in pregnancy only if the potential benefit justifies the potential risk; limited data available.
Patients who are breastfeeding should discuss risks and benefits with their healthcare provider.
Be aware of masking symptoms in patients at risk for gastric malignancy; follow-up diagnostics recommended.
Avoid concurrent use with drugs that are contraindicated or prone to interaction via CYP3A4 or CYP2C19.
Advise patients against crushing or chewing tablets to ensure proper pharmacokinetic profile.
Inform patients about the importance of adherence to prescribed dosing schedules.

Warnings

Risk of serious kidney problems including acute tubulointerstitial nephritis.
Potential for Clostridioides difficile infection leading to severe diarrhea.
Association with increased risk of fractures of hip, wrist, or spine during long-term or high-dose therapy.
Rare but severe skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis.
Possible masking of symptoms related to gastric malignancies; caution with diagnostic interpretation.
Risk of vitamin B12 deficiency with prolonged acid suppression.
Hypomagnesemia can result in serious cardiac and neurological complications if untreated.
Increased risk of the development of fundic gland polyps with extended use beyond one year.
Discontinuation should be medically supervised to prevent rebound acid hypersecretion.
Potential drug interactions that may alter plasma concentrations of concomitant medications.
Use precautionally in patients with liver impairment due to primary hepatic metabolism.
Patients should be monitored for allergic reactions, including severe anaphylaxis.
Avoid use in patients with known hypersensitivity to vonoprazan or any tablet constituents.

Contraindication

Known allergy or hypersensitivity to vonoprazan or any components of Voquezna tablets.
Patients with previous severe reactions to potassium-competitive acid blockers.
Use contraindicated in patients with severe hepatic impairment without dose adjustment and monitoring.
Concurrent use with drugs contraindicated due to interactions involving CYP3A4 leading to severe adverse effects.
Contraindicated in patients with unexplained gastric bleeding until malignancy is ruled out.
Avoid use in patients with known gastric malignancy not adequately treated or diagnosed.
Contraindicated in pediatric populations due to lack of established safety and efficacy data.

Drug Interactions

Atazanavir levels may be affected, requiring close monitoring or avoidance of co-administration.
Digoxin and other medications causing hypomagnesemia may have enhanced toxicity risks when combined.
Nelfinavir metabolism may be altered leading to potential decreased efficacy or toxicity.
Medications containing rilpivirine used for HIV-1 can have altered absorption due to gastric pH changes.
Iron supplements and ketoconazole absorption may be decreased due to increased gastric pH.
CYP3A substrates with narrow therapeutic indices, such as theophylline, may have altered plasma levels.
CYP2C19 substrates like clopidogrel and citalopram could have modified metabolism affecting therapeutic response.
Potential interaction with diuretics increasing risk of electrolyte imbalance.
May interfere with diagnostic tests involving chromogranin A or secretin stimulation; stop drug 14 days prior.
Possible interaction with anticoagulants requiring monitoring of coagulation parameters.
Concomitant use of other acid-suppressing agents may alter effectiveness and increase side effects.
Drugs with pH-dependent solubility may show altered absorption and efficacy.
Caution when used with drugs that prolong QT interval due to potential electrolyte disturbances.
Herbal supplements or over-the-counter drugs affecting CYP enzymes may influence vonoprazan levels.
Monitoring recommended when combining with immunosuppressive agents such as cyclosporine.

Preparations Of The Drug

Available as oral tablets in 10 mg and 20 mg strengths for precise dosing according to indication.
Tablets are film-coated with characteristic coloring: 10 mg tablets contain ferric oxide yellow, 20 mg tablets contain ferric oxide red.
Formulated with excipients such as ascorbic acid and croscarmellose sodium to enhance stability and bioavailability.
Manufactured by Phathom Pharmaceuticals, Inc., ensuring compliance with FDA regulatory standards.
Packaged in both individual bottles and blister packs for patient convenience and compliance.
Available as Voquezna Triple and Dual Pak formulations combined with antibiotics for H. pylori treatment (approved separately).
Storage recommendation is at room temperature between 68°F to 77°F (20°C to 25°C), protected from moisture and light.
Distributed commercially with clear labeling including dosage instructions, contraindications, and side effect warnings.
Tablets designed for swallowing whole without crushing or chewing to maintain pharmacokinetic properties.
Intended for oral administration only, with flexibility to be taken with or without food.
Packaging includes patient information leaflets detailing potential adverse effects and drug interactions.
Additional branded packaging available depending on market and healthcare provider preferences.